中文｜English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Volume 41 Issue 6
Jun.  2025
Turn off MathJax
Article Contents
Article Navigation >  Journal of Clinical Hepatology  > 2025  >  41(6): 1207-1212

Progress on the application of metabolomics in the prevention and treatment of liver failure using traditional Chinese medicine

DOI: 10.12449/JCH250631
  • 1.

    Graduate School，Guangxi University of Chinese Medicine，Nanning 530001，China

  • 2.

    Department of Hepatology，The First Affiliated Hospital of Guangxi University of Chinese Medicine，Nanning 530023，China

Research funding:

National Natural Science Foundation of China (82360912);

National Natural Science Foundation of China (81960841);

National Natural Science Foundation of China (82274434);

Guangxi Natural Science Foundation (2023GXNSFBA026190);

Guangxi University of Traditional Chinese Medicine Doctoral Research Foundation (2021BS028);

Guangxi University of Traditional Chinese Medicine Young Teachers’ Scientific Research Foundation Ability Improvement Project (2022KY0299);

The First Affiliated Hospital of Guangxi University of Traditional Chinese Medicine Scientific Research Project (2021QN004)

More Information
  • Corresponding author: MAO Dewen， mdwboshi2005@163.com （ORCID： 0000-0001-9438-9325）
  • Received Date: 2024-09-04
  • Accepted Date: 2024-11-29
  • Published Date: 2025-06-25
    Abstract
  • With the concurrent development of traditional Chinese medicine （TCM） and metabolomics in the diagnosis and treatment of liver failure， techniques such as nuclear magnetic resonance， mass spectrometry， chromatography， metabolic flux analysis， and bioinformatics enable the qualitative or quantitative analysis of endogenous small molecule metabolites in animal models of liver failure and patients with liver failure. These methods help identify specific biomarkers for early diagnosis and clinical intervention. This article reviews recent advancements in metabolomics for the early diagnosis of liver failure， biomarker discovery， identification of TCM syndromes， and the application of TCM in treating liver failure， aiming to provide a basis for TCM-based diagnosis and treatment of liver failure.

     

    • FullText(HTML)
  • loading
    • References(42)
  • [1]
    XU HQ, LI CY, TANG SH. Research progress on the clinical classification correlation between liver cirrhosis and liver failure[J]. Med J Chin PLA, 2024, 49( 3): 355- 359. DOI: 10.11855/j.issn.0577-7402.0972.2023.1020.

    徐华谦, 李春燕, 汤善宏. 肝硬化与肝衰竭临床分类的相关性研究进展[J]. 解放军医学杂志, 2024, 49( 3): 355- 359. DOI: 10.11855/j.issn.0577-7402.0972.2023.1020.
    [2]
    SHU FM, HUANG Y, MAO DW. Exploration and practice of detoxifying, resolving stasis, and warming Yang method to restore immune balance in HBV-related liver failure[J]. J Clin Hepatol, 2023, 39( 11): 2668- 2673. DOI: 10.3969/j.issn.1001-5256.2023.11.023.

    舒发明, 黄英, 毛德文. 解毒化瘀温阳法重建HBV相关肝衰竭免疫平衡的探索与实践[J]. 临床肝胆病杂志, 2023, 39( 11): 2668- 2673. DOI: 10.3969/j.issn.1001-5256.2023.11.023.
    [3]
    WU FL, MAO DW, WANG MG, et al. Exploring role of pyroptosis in pathogenesis of immune inflammation based on theory of dampness and liver stasis[J]. Liaoning J Tradit Chin Med, 2024, 51( 10): 8- 11. DOI: 10.13192/j.issn.1000-1719.2024.10.003.

    吴凤兰, 毛德文, 王明刚, 等. 基于“湿毒瘀” 病机理论探讨细胞焦亡在肝衰竭免疫炎症发病机制中的作用[J]. 辽宁中医杂志, 2024, 51( 10): 8- 11. DOI: 10.13192/j.issn.1000-1719.2024.10.003.
    [4]
    ZENG MH, DU S, TANG NH, et al. Effect of Yinchenhao Tang and Yinchen Zhufu Tang combined formula on Treg/Th17 Cells in patients with hepatitis B virus related acute-on-chronic liver failure in vitro[J/OL]. Chin J Exp Med Formul, 2024: 1- 10.

    曾孟晖, 杜珊, 谭年花, 等. 茵陈蒿汤与茵陈术附汤合方对乙肝相关性慢加急性肝衰竭患者Treg/Th17细胞体外培养的影响[J/OL]. 中国实验方剂学杂志, 2024: 1- 10.
    [5]
    HUANG CH, GUO JC, XUN YH. Exploring Guo Jinchun’‍s medication experience in treating acute-on-chronic liver failure based on the Traditional Chinese Medicine inheritance assistance platform[J]. Zhejiang J Integr Tradit Chin West Med, 2023, 33( 8): 769- 775.

    黄创豪, 过建春, 荀运浩. 基于中医传承辅助平台探讨过建春治疗慢加急性肝衰竭用药经验[J]. 浙江中西医结合杂志, 2023, 33( 8): 769- 775.
    [6]
    PROCOPET B, FISCHER P, FARCAU O, et al. Metabolomics: From liver chiromancy to personalized precision medicine in advanced chronic liver disease[J]. World J Hepatol, 2018, 10( 3): 371- 378. DOI: 10.4254/wjh.v10.i3.371.
    [7]
    LIU GF, WANG XZ, FAN XL, et al. Metabolomics profiles in acute-on-chronic liver failure: Unveiling pathogenesis and predicting progression[J]. Front Pharmacol, 2022, 13: 953297. DOI: 10.3389/fphar.2022.953297.
    [8]
    MUTHUBHARATHI BC, GOWRIPRIYA T, BALAMURUGAN K. Metabolomics: Small molecules that matter more[J]. Mol Omics, 2021, 17( 2): 210- 229. DOI: 10.1039/d0mo00176g.
    [9]
    ZHANG Y, TAN WT, WANG XB, et al. Metabolic biomarkers significantly enhance the prediction of HBV-related ACLF occurrence and outcomes[J]. J Hepatol, 2023, 79( 5): 1159- 1171. DOI: 10.1016/j.jhep.2023.07.011.
    [10]
    JACOB M, LOPATA AL, DASOUKI M, et al. Metabolomics toward personalized medicine[J]. Mass Spectrom Rev, 2019, 38( 3): 221- 238. DOI: 10.1002/mas.21548.
    [11]
    CHEN L. Discovery and validation of prognostic markers for acute-on-chronic liver failure based on metabolomics[D]. Nanchang: Nanchang University, 2020.

    陈玲. 基于代谢组学的慢加急性肝衰竭疾病预后标志物的发现和确证[D]. 南昌: 南昌大学, 2020.
    [12]
    ZHOU X, LAI Y. Research advances in the identification of clinical biomarkers for liver diseases using metabolomics based on ultra-performance liquid chromatography-mass spectrometry.[J] J Clin Hepatol, 2017, 33( 5): 979- 984. DOI: 10.3969/j.issn.1001-5256.2017.05.040.

    周玄, 赖泳. 基于超高效液相色谱-质谱的代谢组学在肝脏疾病生物标志物发现中的作用[J]. 临床肝胆病杂志, 2017, 33( 5): 979- 984. DOI: 10.3969/j.issn.1001-5256.2017.05.040.
    [13]
    XUE Y, ZHANG XJ, LU JC, et al. Analysis of the characteristics of peripheral blood serum metabolomics in HBV-related acute-on-chronic liver failure[C]. The 11th National Conference on Difficult and Critical Liver Diseases. Changzhou, 2021.

    薛源, 张秀军, 陆建春, 等. 乙肝病毒相关慢加急性肝衰竭外周血清代谢组学特点分析[C]. 第11届全国疑难及重症肝病大会. 常州, 2021.
    [14]
    ZHOU GL. Metabolomics research reveals that the serum lactate/ creatinine ratio is a potential biomarker for artificial liver treatment in liver failure[D]. Nanchang: Nanchang University, 2019.

    周观林. 代谢组学研究揭示: 血清乳酸/肌酐比值为肝衰竭人工肝治疗的潜在标志物[D]. 南昌: 南昌大学, 2019.
    [15]
    ZHOU C, TANG Q, HE ZY, et al. Targeted amino acid metabolomics unveils the biological underpinnings of subtypes of jaundice in hepatitis B-related acute-on-chronic liver failure[J]. Chin J Integr Tradit West Med Liver Dis, 2024, 34( 6): 484- 489. DOI: 10.3969/j.issn.1005-0264.2024.006.002.

    周超, 唐巧, 何召云, 等. 基于靶向氨基酸代谢组学探讨乙型病毒性肝炎相关慢加急性肝衰竭瘀黄证亚型的生物学基础[J]. 中西医结合肝病杂志, 2024, 34( 6): 484- 489. DOI: 10.3969/j.issn.1005-0264.2024.006.002.
    [16]
    YU M, ZHOU C, TIAN D, et al. Molecular classification and clinical diagnosis of acute-on-chronic liver failure patients by serum metabolomics[J]. J Pharm Biomed Anal, 2021, 198: 114004. DOI: 10.1016/j.jpba.2021.114004.
    [17]
    ZHU ZM, CUI BM, YANG JB, et al. Effect of Mahuang decoction on the immune barrier function of nasal mucosa in model rats[J]. China Pharm, 2024, 33( 20): 38- 45.

    朱紫陌, 崔白梅, 杨居崩, 等. 麻黄汤对模型大鼠鼻黏膜免疫屏障功能的影响[J]. 中国药业, 2024, 33( 20): 38- 45.
    [18]
    YAMADA I, GOTO T, TAKEUCHI S, et al. Mao(Ephedra sinica Stapf) protects against D-galactosamine and lipopolysaccharide-induced hepatic failure[J]. Cytokine, 2008, 41( 3): 293- 301. DOI: 10.1016/j.cyto.2007.12.003.
    [19]
    WU ZP, KONG XL, ZHANG T, et al. Pseudoephedrine/ephedrine shows potent anti-inflammatory activity against TNF-α-mediated acute liver failure induced by lipopolysaccharide/D-galactosamine[J]. Eur J Pharmacol, 2014, 724: 112- 121. DOI: 10.1016/j.ejphar.2013.11.032.
    [20]
    LIAO WT, JIN QW, LIU JN, et al. Mahuang decoction antagonizes acute liver failure via modulating tricarboxylic acid cycle and amino acids metabolism[J]. Front Pharmacol, 2021, 12: 599180. DOI: 10.3389/fphar.2021.599180.
    [21]
    LI XH, YANG HS. Qian Ying‍’‍s experience in the treatment of chronic severe hepatitis by‘Jieduan-Niwan formula method’.[J]. Chin J Integr Tradit West Med Liver Dis, 2006, 16( 6): 362- 365. DOI: 10.3969/j.issn.1005-0264.2006.06.017.

    李秀惠, 杨华升. 钱英“截断逆挽法” 治疗慢性重型肝炎的经验[J]. 中西医结合肝病杂志, 2006, 16( 6): 362- 365. DOI: 10.3969/j.issn.1005-0264.2006.06.017.
    [22]
    HAO YL, YANG WL, HOU WX, et al. Regulation mechanism of Jieduan Niwan formula on E2F1 signaling pathway in rats with acute-on-chronic hepatic failure[J]. Glob Tradit Chin Med, 2018, 11( 3): 321- 326. DOI: 10.3969/j.issn.1674-1749.2018.03.001.

    郝玉林, 杨文龙, 侯伟欣, 等. 截断逆挽方对慢加急性肝衰竭大鼠E2F1信号通路的调节机制[J]. 环球中医药, 2018, 11( 3): 321- 326. DOI: 10.3969/j.issn.1674-1749.2018.03.001.
    [23]
    CHEN H, LI XH. Professor Li Xiuhui’s“Truncated Reversal Method” in the treatment of chronic liver failure[J]. Chin J Integr Tradit West Med Liver Dis, 2021, 31( 1): 21- 22, 25. DOI: 10.3969/j.issn.1005-0264.2021.01.005.

    陈欢, 李秀惠. 李秀惠教授运用截断逆挽法治疗慢性肝衰竭验案[J]. 中西医结合肝病杂志, 2021, 31( 1): 21- 22, 25. DOI: 10.3969/j.issn.1005-0264.2021.01.005.
    [24]
    JIANG XJ, FANG X, HOU WX, et al. Study on the effect of JieDuan NiWan formula on the cell entering S phase in rats with acute-on-chronic liver failure[J]. Chin J Integr Tradit West Med Liver Dis, 2021, 31( 1): 11- 15. DOI: 10.3969/j.issn.1005-0264.2021.01.003.

    姜雪娇, 方娴, 侯伟欣, 等. 截断逆挽方对慢加急性肝衰竭大鼠肝细胞进入S期关键蛋白的影响[J]. 中西医结合肝病杂志, 2021, 31( 1): 11- 15. DOI: 10.3969/j.issn.1005-0264.2021.01.003.
    [25]
    FANG X, JIANG XJ, HOU WX, et al. Study on the mechanism of Jieduan Niwan formula on cyclin D-E2F1 signaling pathway and transcription factor activation of rats with acute-on-chronic liver failure[J]. Glob Tradit Chin Med, 2021, 14( 4): 549- 555. DOI: 10.3969/j.issn.1674-1749.2021.04.001.

    方娴, 姜雪娇, 侯伟欣, 等. 截断逆挽方对慢加急性肝衰竭大鼠cyclin D-E2F1信号通路及转录因子活化的机制研究[J]. 环球中医药, 2021, 14( 4): 549- 555. DOI: 10.3969/j.issn.1674-1749.2021.04.001.
    [26]
    DOU B, MA CY, HOU WX, et al. Effects of Jieduan Niwan Prescription drug containing serum on oxidative stress injury of L02 cells based on TLR4/NF-κB/iNOS pathwayv[J]. Chin J Inf Tradit Chin Med, 2022, 29( 4): 87- 91. DOI: 10.19879/j.cnki.1005-5304.202110034.

    窦博, 马重阳, 侯伟欣, 等. 基于TLR4/NF-κB/iNOS通路的截断逆挽方药物血清对L02细胞氧化应激损伤的影响[J]. 中国中医药信息杂志, 2022, 29( 4): 87- 91. DOI: 10.19879/j.cnki.1005-5304.202110034.
    [27]
    LIANG JJ, WEI XY, HOU WX, et al. Liver metabolomics reveals potential mechanism of Jieduan-Niwan formula against acute-on-chronic liver failure(ACLF) by improving mitochondrial damage and TCA cycle[J]. Chin Med, 2023, 18( 1): 157. DOI: 10.1186/s13020-023-00858-x.
    [28]
    LONG FL, LIN Y, FENG F, et al. Analysis of urine metabonomics of acute liver failure rats treated with jieduhuayu granule based on LC-MS[J]. Lishizhen Med Mater Med Res, 2021, 32( 7): 1551- 1555. DOI: 10.3969/j.issn.1008-0805.2021.07.04.

    龙富立, 林镛, 冯逢, 等. 基于LC-MS分析解毒化瘀颗粒对急性肝衰竭大鼠的尿液代谢组学的影响[J]. 时珍国医国药, 2021, 32( 7): 1551- 1555. DOI: 10.3969/j.issn.1008-0805.2021.07.04.
    [29]
    AHMED T, WANG CK. Black garlic and its bioactive compounds on human health diseases: A review[J]. Molecules, 2021, 26( 16): 5028. DOI: 10.3390/molecules26165028.
    [30]
    STĘPIEŃ AE, TROJNIAK J, TABARKIEWICZ J. Anti-cancer and anti-inflammatory properties of black garlic[J]. Int J Mol Sci, 2024, 25( 3): 1801. DOI: 10.3390/ijms25031801.
    [31]
    WU ZG, JIN N, DENG YF, et al. Protective action of selenium-enriched black garlic extract in rats with lipopolysaccharide/D-galactosamine-induced acute liver failure[J]. J Funct Foods, 2024, 115: 106123. DOI: 10.1016/j.jff.2024.106123.
    [32]
    ZHOU CH, HUANG Y, NIE S, et al. Biological effects and mechanisms of fisetin in cancer: A promising anti-cancer agent[J]. Eur J Med Res, 2023, 28( 1): 297. DOI: 10.1186/s40001-023-01271-8.
    [33]
    JIANG YZ, TANG XW, DENG P, et al. The neuroprotective role of fisetin in different neurological diseases: A systematic review[J]. Mol Neurobiol, 2023, 60( 11): 6383- 6394. DOI: 10.1007/s12035-023-03469-7.
    [34]
    ZOU TF, LIU ZG, CAO PC, et al. Fisetin treatment alleviates kidney injury in mice with diabetes-exacerbated atherosclerosis through inhibiting CD36/fibrosis pathway[J]. Acta Pharmacol Sin, 2023, 44( 10): 2065- 2074. DOI: 10.1038/s41401-023-01106-6.
    [35]
    ZHAO L, ZHANG J, PAN L, et al. Protective effect of 7, 3’, 4’-flavon-3-ol(fisetin) on acetaminophen-induced hepatotoxicity in vitro and in vivo[J]. Phytomedicine, 2019, 58: 152865. DOI: 10.1016/j.phymed.2019.152865.
    [36]
    ZHANG J, ZHOU XM. Artificial liver support therapy for patients with pre-liver failure[J]. J Clin Hepatol, 2024, 40( 2): 229- 232. DOI: 10.12449/JCH240202.

    张静, 周新民. 肝衰竭前期的人工肝治疗[J]. 临床肝胆病杂志, 2024, 40( 2): 229- 232. DOI: 10.12449/JCH240202.
    [37]
    Liver Failure and Artificial Liver Group, Chinese Society of Infectious Diseases, Chinese Medical Association; Severe Liver Disease and Artificial Liver Group, Chinese Society of Hepatology, Chinese Medical Association. Guideline for diagnosis and treatment of liver failure(2018)[J]. J Clin Hepatol, 2019, 35( 1): 38- 44. DOI: 10.3969/j.issn.1001-5256.2019.01.007.

    中华医学会感染病学分会肝衰竭与人工肝学组, 中华医学会肝病学分会重型肝病与人工肝学组. 肝衰竭诊治指南(2018年版)[J]. 临床肝胆病杂志, 2019, 35( 1): 38- 44. DOI: 10.3969/j.issn.1001-5256.2019.01.007.
    [38]
    LI ZY, ZHU XY, LI CH, et al. Integrated serum metabolomics, 16S rRNA sequencing and bile acid profiling to reveal the potential mechanism of gentiopicroside against nonalcoholic steatohepatitis in lean mice[J]. J Ethnopharmacol, 2024, 334: 118526. DOI: 10.1016/j.jep.2024.118526.
    [39]
    SU LL, MAO J, HAO M, et al. Integrated plasma and bile metabolomics based on an UHPLC-Q/TOF-MS and network pharmacology approach to explore the potential mechanism of Schisandra chinensis-protection from acute alcoholic liver injury[J]. Front Pharmacol, 2020, 10: 1543. DOI: 10.3389/fphar.2019.01543.
    [40]
    LIU YR, CHEN H, YANG GJ, et al. Metabolomics and serum pharmacochemistry combined with network pharmacology uncover the potential effective ingredients and mechanisms of Yin-Chen-Si-Ni Decoction treating ANIT-induced cholestatic liver injury[J]. J Ethnopharmacol, 2024, 335: 118713. DOI: 10.1016/j.jep.2024.118713.
    [41]
    ZHENG WW, NING K, SHI C, et al. Xiaobugan decoction prevents CCl4-induced acute liver injury by modulating gut microbiota and hepatic metabolism[J]. Phytomedicine, 2024, 135: 156113. DOI: 10.1016/j.phymed.2024.156113.
    [42]
    WANG C, FU RJ, XU DQ, et al. A study integrated metabolomics and network pharmacology to investigate the effects of Shicao in alleviating acute liver injury[J]. J Ethnopharmacol, 2024, 319( Pt 3): 117369. DOI: 10.1016/j.jep.2023.117369.
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索
    Get Citation
    PDF
    XML

    Article Metrics

    Article views (442) PDF downloads(20) Cited by()
    Proportional views
    Related
        

    The first journal specializing in hepatobiliary and pancreatic diseases in China

    Supervisor：Ministry of Education of the People's Republic of China

    Sponsor：Jilin University

    Academic Support: Chinese Society of Hepatology，Chinese Medical Association

    Address: 461 Xinjiang Road, Changchun

    Submit：0431-88782044

    Peer review：0431-88783542

    Email：lcgdb@vip.163.com

    About Journal

    Submission Guideline

    Journal Online

    Hepatobiliary College

    Guidelines

    YesterdayIP[]YesterdayPV[]TodayIP[]TodayPV[]Online[]

    Website Design © 2020 Editorial Board of Journal of Clinical Hepatology 吉ICP备10000617号-1 Supported by: Beijing Renhe Information Technology Co. Ltd  

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return